These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31527921)

  • 1. Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis.
    Liu WN; Chang CF; Chung CH; Chien WC; Huang TC; Wu YY; Ho CL; Chen JH
    PLoS One; 2019; 14(9):e0222522. PubMed ID: 31527921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
    Huang J; Phillips S; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Jagasia M; Kassim A; Rawling KT; Savani BN; Sengsayadeth S; Cornell RF
    Bone Marrow Transplant; 2018 Jun; 53(6):701-707. PubMed ID: 29703965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.
    Liu Y; Tang CH; Qiu H; Siggins S; Hou HA
    Sci Rep; 2021 Jan; 11(1):1112. PubMed ID: 33441901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma.
    Modi D; Chi J; Kim S; Ayash L; Alavi A; Kin A; Ratanatharathorn V; Uberti JP; Deol A
    Leuk Lymphoma; 2020 Aug; 61(8):1877-1884. PubMed ID: 32270725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation--a single institutional experience in Taiwan.
    Huang TC; Chen JH; Wu YY; Chang PY; Dai MS; Chao TY; Kao WY; Chen YC; Ho CL
    Ann Hematol; 2015 Jan; 94(1):107-15. PubMed ID: 25047657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
    Straka C; Knop S; Vogel M; Müller J; Kropff M; Metzner B; Langer C; Sayer H; Jung W; Dürk HA; Salwender H; Wandt H; Bassermann F; Gramatzki M; Rösler W; Wolf HH; Brugger W; Fischer T; Liebisch P; Engelhardt M; Einsele H
    Eur J Haematol; 2019 Sep; 103(3):255-267. PubMed ID: 31231828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis.
    Lu J; Lu J; Liu A; Fu W; Du J; Huang X; Chen W; Hou J
    Biomed Res Int; 2015; 2015():856704. PubMed ID: 26640799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma.
    Saraceni MM; Scott E; Maziarz RT; Siegel MB; Bassale S; Jiing S; Medvedova E
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e77-e84. PubMed ID: 29169873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.
    Hock BD; Mulholland KS; Ganly P; McKenzie JL; Pearson JF; MacPherson SA
    Intern Med J; 2019 May; 49(5):598-606. PubMed ID: 30411451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation.
    Chan H; Phillips M; Maganti M; Farooki S; Piza Rodriguez G; Masih-Khan E; Chen C; Prica A; Reece D; Tiedemann R; Trudel S; Kukreti V
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):225-234. PubMed ID: 29397346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin D Multiple Myeloma: Disease Profile, Therapeutic Response, and Survival.
    Wang GR; Sun WJ; Chen WM; Huang ZX; Zhang JJ; An N; Shen M; Li X
    Acta Haematol; 2016; 136(3):140-6. PubMed ID: 27409804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
    Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy.
    Kurihara K; Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Hatta Y; Nakayama T; Takei M
    Med Oncol; 2019 Jul; 36(9):75. PubMed ID: 31342211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
    Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
    Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
    Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
    Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
    Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
    Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
    Hao QY; Chen H; Liu KY; Wen L; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):689-94. PubMed ID: 27586976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.